NCT05239741 2026-04-17
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
85 trialsNCT07284849 2026-04-16
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT02997228 2026-04-13
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06750094 2026-04-13
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07525206 2026-04-13
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Not yet recruiting
NCT07222800 2026-04-08
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT05253651 2026-04-07
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT07228832 2026-04-06
HARMONi-GI3
Summit Therapeutics
Phase 3 Recruiting
NCT06252649 2026-04-02
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT05863195 2026-03-23
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT04230187 2026-03-05
TRIBE-C
Sun Yat-sen University
Phase 3 Recruiting
NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
NCT07389265 2026-02-05
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Phase 3 Recruiting
NCT04854668 2026-01-30
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT06791512 2025-12-24
BASKETâ…¢
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT06733038 2025-12-08
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
NCT06614192 2025-08-26
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT03828227 2025-07-18
COLAGE
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Active not recruiting
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06992648 2025-05-28
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT02934529 2025-04-16
AIO-KRK-0114
Ludwig-Maximilians - University of Munich
Phase 3 Completed
NCT02162563 2025-02-06
CAIRO5
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT01878422 2025-01-31
ITACa
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3 Completed
NCT03511963 2024-12-31
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
Shanghai Henlius Biotech
Phase 3 Completed
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT04687631 2024-12-18
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Recruiting
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03635021 2024-10-21
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Active not recruiting
NCT02563002 2024-10-03
KEYNOTE-177
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04737187 2024-09-24
SUNLIGHT
Taiho Oncology, Inc.
Phase 3 Completed
NCT06566755 2024-08-22
Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer
Shengjing Hospital
Phase 3 Recruiting
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT05797467 2023-05-24
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT01718873 2023-04-12
OBELICS
National Cancer Institute, Naples
Phase 3 Completed
NCT00642577 2022-12-22
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT05540951 2022-09-15
VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer
Fudan University
Phase 3 Unknown
NCT04188145 2021-10-28
BEVAMAINT
Centre Hospitalier Universitaire Dijon
Phase 3 Unknown
NCT04781270 2021-09-27
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Fudan University
Phase 3 Unknown
NCT03288987 2021-01-22
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
AryoGen Pharmed Co.
Phase 3 Completed
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00544700 2020-02-20
Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
Swiss Cancer Institute
Phase 3 Terminated